beta-D-Galactoside alpha 2-6-Sialyltransferase

Sialyltransferases that catalyze the transfer of N-ACETYLNEURAMINIC ACID from CYTIDINE MONOPHOSPHATE N-ACETYLNEURAMINIC ACID to the 6-OH of the GALACTOSE residue of N-GLYCANS.

Also Known As:

Gal-GlcNAc(2-6)-sialyltransferase; SIAT-1; ST6(N); ST6Gal I; ST6Gal-1; 2-6-Sialyltransferase, alpha; 2-6-Sialyltransferase, beta-D-Galactoside alpha; Acid-Lactose Sialytransferase, CMP-N-Acetylneuraminic; CMP N Acetylneuraminate Galactosylglycoprotein Sialyltransferase ST6GAL; CMP N Acetylneuraminate beta Galactoside alpha 2,6 Sialyltransferase; CMP N Acetylneuraminic Acid Lactose Sialytransferase; SIAT 1; ST6GAL, CMP-N-Acetylneuraminate-Galactosylglycoprotein Sialyltransferase; ST6Gal 1; Sialyltransferase ST6GAL, CMP-N-Acetylneuraminate-Galactosylglycoprotein; Sialytransferase, CMP-N-Acetylneuraminic Acid-Lactose; alpha 2 6 Sialyltransferase; alpha 2-6-Sialyltransferase, beta-D-Galactoside; alpha-2,6-Sialyltransferase, CMP-N-Acetylneuraminate-beta-Galactoside; alpha-2-6-Sialyltransferase, beta-D-Galactoside; alpha2,6-Sialyltransferase, beta-Galactoside; alpha6 Sialyltransferase; beta D Galactoside alpha 2 6 Sialyltransferase; beta Galactoside alpha2,6 Sialyltransferase; CMP-Acetylneuraminate Galactoside (alpha 2-6)-Sialyltransferase; CMP-N-Acetylneuraminate-Galactosylglycoprotein Sialyltransferase ST6GAL; CMP-N-Acetylneuraminate-beta-Galactoside alpha-2,6-Sialyltransferase; CMP-N-Acetylneuraminic Acid-Lactose Sialytransferase; CMP-NeuAc-Galactoside (alpha 2-6)-Sialyltransferase; CMP-Sialic Acid-N-Acetyllactosaminide alpha (2-6)-Sialyltransferase; Gal-1-4-GlcNAc alpha(2-6)-Sialyltransferase; alpha 2-6-Sialyltransferase; alpha2,6(N) Sialyltransferase; alpha6-Sialyltransferase; beta-D-Galactoside alpha-2-6-Sialyltransferase; beta-Galactoside alpha2,6-Sialyltransferase; beta-Galactosyl(1-4)N-Acetylglucosaminide alpha(2-6)-Sialyltransferase

Networked: 73 relevant articles (0 outcomes, 15 trials/studies)

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Transferases: 6589
    - Glycosyltransferases: 784
      - Sialyltransferases: 490
        beta-D-Galactoside alpha 2-6-Sialyltransferase: 73
        human ST6GAL1 protein

Experts

1.	Lau, Joseph T Y: 4 articles (01/2019 - 03/2010)
2.	Lee, Minyoung: 4 articles (11/2016 - 08/2008)
3.	Li, Hong: 4 articles (03/2007 - 01/2007)
4.	Nasirikenari, Mehrab: 3 articles (01/2019 - 11/2006)
5.	Park, Jung-Jin: 3 articles (11/2016 - 03/2010)
6.	Lee, Yun-Sil: 3 articles (03/2012 - 08/2008)
7.	Taniguchi, Naoyuki: 3 articles (09/2010 - 03/2005)
8.	Wang, Peng-Hui: 3 articles (04/2007 - 07/2002)
9.	Yuan, Chiou-Chung: 3 articles (04/2007 - 07/2002)
10.	Chiricolo, Mariella: 3 articles (02/2006 - 01/2004)

Related Diseases

1.	Carcinoma (Carcinomatosis) 01/01/2007 - "To study the effects of antisense oligonucleotide (ASODN) targeting ST6Gal I on cell adhesion and invasiveness of human cervical carcinoma cell line HeLa which over-expressed ST6Gal I . " 01/01/2007 - "To study the effect of synthesized ST6Gal I specific siRNA on the adhesion and invasiveness of human colon carcinoma cell line SW480 with over expression of ST6Gal I. A double strand small interference RNA (siRNA) targeting ST6Gal I was designed and synthesized, and then transfected into SW480 cells by lipofectmine 2000. " 10/01/2000 - "RT-PCR analysis of 14 carcinoma samples, all expressing an increased ST6Gal.I enzyme activity, and of the corresponding normal mucosa revealed the presence of at least 2 transcripts. " 02/01/2007 - "To study the effects of small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) targeting ST6Gal I on adhesion and invasiveness of human colonic carcinoma cell line SW480 over-expressing ST6Gal I. siRNA and ASOs targeting ST6Gal I were constructed and transfected into SW480 cells via lipofectmine 2000. " 02/01/2007 - "[ST6Gal I siRNA and antisense oligonucleotide-mediated gene silencing lowers the invasiveness potential of colonic carcinoma cells]."
2.	Colonic Neoplasms (Colon Cancer) 03/27/2012 - "Both non-cleaved and cleaved forms of ST6Gal I significantly increased colon cancer cell migration in a sialylation-dependent manner. " 02/01/2006 - "Phenotypic changes induced by expression of beta-galactoside alpha2,6 sialyltransferase I in the human colon cancer cell line SW948." 08/08/2003 - "Transcriptional regulation of human beta-galactoside alpha2,6-sialyltransferase (hST6Gal I) gene in colon adenocarcinoma cell line." 05/31/2001 - "Expression of ST6Gal I and its products is reportedly increased in colon cancers. " 04/12/1999 - "Differential expression of the hepatic transcript of beta-galactoside alpha2,6-sialyltransferase in human colon cancer cell lines."
3.	Inflammation (Inflammations) 11/15/2006 - "Together, our study demonstrated a role for ST6Gal-1, possibly from extramedullary sources (eg, produced in liver) in regulating inflammation, circulating neutrophil homeostasis, and replenishing granulocyte numbers." 01/01/2019 - "Taken together, the data advance the idea that manipulating circulatory ST6Gal-1 levels has potential in managing inflammatory conditions by leveraging the combined approaches of controlling new inflammatory cell production and dampening the inflammation mediator cascade." 03/01/2010 - "Taken together, the data implicate ST6Gal-1 as a participant in regulating not only Th1 but also Th2 responses, and ST6Gal-1 deficiency can lead to the development of more severe allergic inflammation with excessive eosinophil production." 03/01/2010 - "The severity of airway inflammation was similar between Siat1DeltaP1 and Siat1 null mice, indicating a role for P1-generated ST6Gal-1 in regulating eosinophilic inflammation. " 03/01/2010 - "We noted previously greater neutrophilic inflammation associated with ST6Gal-1 deficiency. "
4.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 06/01/2003 - "Enhanced expression of alpha 2,6-sialyltransferase ST6Gal I in cervical squamous cell carcinoma." 03/01/2009 - "Increased mRNA expression of STs (ST6Gal I, ST3Gal III) has been detected in invasive cervical squamous cell carcinoma. " 10/01/2001 - "ST6Gal I expression was enhanced in squamous cell carcinoma of the cervix (P = 0.026, Mann-Whitney U test), but mRNA expression from the other three STs (ST3Gal I, ST3Gal III, and ST3Gal IV) was significantly down-expressed in squamous cell carcinoma of the cervix compared to the normal cervix (P = 0.003, P < 0.001, and P = 0.001, respectively). " 02/14/2013 - "In summary, our results showed that the high expression of ST3Gal I and ST6Gal I, in skin tumors, is associated with tumors with greater potential for invasion and metastasis, as in the case of squamous cell carcinoma, and this may be related to their behavior." 02/14/2013 - "The expression of ST3Gal I was observed in actinic keratosis (53%), keratoacanthoma (78%), squamous cell carcinoma (73%) and basal cell carcinoma (32%) with statistic differences between basal cell carcinoma and keratoacanthoma (P=0.0239) and basal cell carcinoma and squamous cell carcinoma (P=0.0096); for ST6Gal I, cytoplasmic expression was noted in actinic keratosis (40%), heterogeneous and cytoplasmic expression was noted in keratoacanthoma (67%), squamous cell carcinoma (41%) and basal cell carcinoma (7%) with statistic differences between basal cell carcinoma and squamous cell carcinoma (P=0.0061) and basal cell carcinoma and keratoacanthoma (P=0.0008). "
5.	Neoplasms (Cancer) 04/24/2015 - "However, the increased α2,6 sialylation catalyzed by β-galactoside α2,6 sialyltranferase 1 (ST6Gal I) is frequently observed in many types of the cancers. " 03/27/2012 - "Here, we further investigated the mechanisms underlying ST6Gal I cleavage, solubilization and release from cells, and addressed its functions, focusing primarily on cancer cell migration. " 11/14/2005 - "Univariate analyses showed that both decreased tumor ST6Gal I activity (P = 0.028), increased serum msAFP percentage (P = 0.034) and poor tumor cell differentiation (P = 0.031) were associated with shorter overall survival. " 11/14/2005 - "Both decreased tumor ST6Gal I activity and increased serum msAFP percentage were associated with poor tumor cell differentiation. " 11/14/2005 - "The tumor ST6Gal I activity was negatively correlated with serum msAFP percentage (r = -0.53, P = 0.019). "

Related Drugs and Biologics

1.	Sialyltransferases
2.	beta-D-Galactoside alpha 2-6-Sialyltransferase
3.	beta-Galactoside alpha-2,3-Sialyltransferase
4.	Enzymes
5.	Small Interfering RNA (siRNA)
6.	Antisense Oligonucleotides
7.	N-Acetylneuraminic Acid (Sialic Acid)
8.	Complementary DNA (cDNA)
9.	Messenger RNA (mRNA)
10.	Lectins

Related Therapies and Procedures

1.	Chemoradiotherapy
2.	Subcutaneous Injections
3.	Aftercare (After-Treatment)